|
|
|
| Clinical effect of Kunxian Capsules combined with Valsartan in the treatment of diabetic nephropathy stage Ⅳ proteinuria |
| WANG Huimin1 WU Yiwei2 CHEN Zhixian3 |
1.Department of Nephropathy, Tangshan Hospital of Traditional Chinese Medicine, Hebei Province, Tangshan 063000, China;
2.Department of General Surgery, Tangshan Hospital of Traditional Chinese Medicine, Hebei Province, Tangshan 063000, China;
3.School of Medicine, Ji′nan University, Guangdong Province, Guangzhou 510630, China |
|
|
|
Abstract Objective To explore the clinical effect of Kunxian Capsules combined with Valsartan in the treatment of diabetic nephropathy stage Ⅳ proteinuria. Methods Sixty-one patients with diabetic nephropathy stage Ⅳ admitted to Tangshan Hospital of Traditional Chinese Medicine, Hebei Province from January 2018 to January 2019 were selected. According to the random number table method, they were divided into the control group and the observation group. Thirty patients in the control group were treated with Valsartan, and thirty-one patients in the observation group were treated with Kunxian Capsules on the basis of the control group. The treatment course of the two groups was 3 months. The changes of quantitative comparison of 24-hour urinary protein , renal function index(blood urea nitrogen [BUN], serum creatinine [Scr], endogenous creatinine clearance rate [Ccr]), liver function index (plasma albumin [Alb], alanine aminotransferase [ALT], aspartate aminotransferase [AST]) and peripheral blood leukocyte (WBC) of the two groups before and after treatment were observed and the adverse reactions were monitored. Results Before treatment, the quantitative comparison of 24-hour urinary protein between the two groups was not statistically significant difference (P ＞ 0.05). After treatment, the quantitative comparison of 24-hour urinary protein in both groups was lower than that before treatment, and the observation group was lower than the control group, and the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). There were no statistically significant differences in BUN, Scr, Ccr, Alb, ALT, AST and WBC levels between the two groups before and after treatment (P ＞ 0.05). No serious side effects were found that required drug withdrawal. Conclusion Kunxian Capsules combined with Valsartan is effective in the treatment of diabetic nephropathy stage Ⅳ, which can effectively reduce the level of patients with diabetic nephropathy proteinuria, so as to better protect renal function, and its safety is good, worthy of clinical promotion and application.
|
|
|
|
|
|
[1] 李惠秀，曹文富.糖尿病肾病发病机制及治疗进展[J].重庆医学，2013，42（21）：2545-2547，2568.
[2] 江岸林，褚小燕，万华堂，等.小剂量雷公藤多苷对糖尿病肾病蛋白尿影响的临床观察[J].中国中西医结合肾病杂志，2014，15（5）：444-445.
[3] 郭艳红，谭垦.雷公藤的毒性及其研究概况[J].中药材，2007，30（1）：112-117.
[4] 方铁岩.昆仙胶囊治疗类风湿关节炎40例临床观察[J].中国民间疗法，2017，25（7）：63.
[5] 王海燕.肾脏病学[M].2版.北京：人民卫生出版社，2008：56.
[6] 国家中医药管理局医政司.22个专业95个病种中医诊疗方案[M].北京：中国中医药出版社，2011：209.
[7] 陈志宏，颜勇，宋成军，等.糖尿病肾病发病机制研究进展[J].承德医学院学报，2010，27（2）：184-186.
[8] 王娜，邹大威.糖尿病肾病足细胞损伤机制的研究进展[J].医学综述，2019，25（20）：4087-4092.
[9] 姜梅玲.固肾方治疗Ⅳ期糖尿病肾病的临床疗效观察[J].山西医药杂志，2019，48（19）：2363-2365.
[10] 李雪侠，王锋，陈刚，等.胰激肽原酶联合缬沙坦对糖尿病肾病Ⅳ期患者的临床疗效研究[J].中国实用医药，2019， 14（25）：93-95.
[11] 王飞，孙伟，张峰.缬沙坦在2型糖尿病肾病患者治疗中的应用效果及机制探讨[J].山东医药，2019，59（26）：71-73.
[12] 刘云.缬沙坦胶囊用于糖尿病肾病治疗的效果观察[J].糖尿病新世界，2018，21（3）：179-180.
[13] Fornoni A，Ijaz A，Tejada T，et al. Role of inflammation in diabetic nephropathy [J]. Curr diabetes Rev，2008，4（1）：10-17.
[14] 汤勇.昆明山海棠的免疫抑制机理研究进展[J].云南医药，2005，26（3）：289-290.
[15] 韩进庭.昆明山海棠药物作用及临床应用研究进展[J].现代医药卫生，2009，25（16）：2459-2460.
[16] 王特，李兆福，李涛，等.昆明山海棠治疗类风湿关节炎作用机制的研究进展[J].风湿病与关节炎，2019，8（8）：60-63.
[17] 杨丽平，赵世萍，李可明，等.昆仙胶囊对阳离子化牛血清白蛋白所致大鼠肾病模型的保护作用[J].中国中西医结合肾病杂志，2009，12（10）：1046-1049，1139.
[18] 严美花，张浩军，王康，等.昆仙胶囊对阿霉素诱导的肾病综合征大鼠的治疗作用[J].中药药理与临床，2011， 27（2）：100-104.
[19] 项协隆，邵思思，黄蔚霞.昆仙胶囊治疗狼疮肾炎伴肾病综合征患者的肾功能及血清IgEIgG水平改善研究[J].中国药物与临床，2019，19（5）：710-713.
[20] 李慧，刘枚，潘文友，等.昆仙胶囊治疗狼疮性肾炎的疗效和安全性研究[J].中国中西医结合杂志，2019，39（9）：1061-1064.
[21] 陈瑶，刘涵.昆仙胶囊联合中医辨证治疗小儿过敏性紫癜性肾炎50例临床疗效观察[J].中医临床研究，2018， 10（16）：58-59.
[22] 邓晓蔚，熊有明，张维，等.昆仙胶囊联合百令胶囊治疗慢性肾小球肾炎临床研究[J].中国药业，2019，28（9）：53-55.
[23] 鲁冰，任东升.昆仙胶囊对原发性膜性肾病患者内皮细胞功能及血清TGF-β1的影响[J].新中医，2019，51（8）：144-147.
[24] 吕艳，于为民，任小军，等.昆仙胶囊联合小剂量激素治疗肾病综合征疗效观察[J].中国药物与临床，2018，18（11）：1934-1935.
[25] 曾佳丽，姜雪，余瑾，等.昆仙胶囊对IgA肾病大鼠的肾保护作用及系膜细胞增殖的影响[J].中国现代医生，2019， 57（31）：38-42，封3.
[26] 黎明阳.昆仙胶囊治疗115例慢性肾脏病的临床疗效观察[D].辽宁：中国医科大学，2018. |
|
|
|
